Indication

Post-acute COVID-19 Respiratory Disease

1 clinical trial

1 product

Clinical trial

A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease

Status: Terminated, Estimated PCD: 2022-06-28

Product